Pharmaceutical industry – Page 9
-
BusinessSartan contaminant recall hits generics manufacturers
Three European suppliers recalling multiple batches of medicines owing to active ingredient contamination
-
BusinessUS judge rules against GSK in trade secrets dispute
Firm will not receive compensation for claimed loses of over $1bn from theft of confidential information by two former scientists
-
BusinessBMS and Eisai agree antibody-drug conjugate commercialisation deal
Companies will jointly develop cancer treatment, with BMS paying up to $3 billion for shared rights
-
BusinessRegeneron’s Covid-19 antibodies help those who can’t make their own
Regn-Cov2 reduces deaths and shortens hospitalisation for these patients, even when given at late stages of infection
-
BusinessAlzheimer’s antibody gets surprise US approval
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients
-
ResearchProtein impurities found in AstraZeneca’s Covid-19 vaccine stir debate
Compounds might cause side effects but are unlikely to be behind extremely rare blood-clotting events
-
BusinessMorphosys agrees to buy cancer epigenetics specialist Constellation
$1.7bn deal will be funded by selling rights to royalties on existing drugs
-
BusinessUS supreme court will not hear J&J talc appeal
Decision means J&J must pay $2.1 billion previously awarded to 22 women who say talc caused their ovarian cancer
-
WebinarThe age of digital chemistry
Join us to learn how data can solve existing bottlenecks in synthetic chemistry and why data analysis demands a multidisciplinary approach
-
BusinessStriving to bolster the antibiotic pipeline before it becomes the next crisis
It’s been almost 10 years since the world was warned of a post-antibiotic apocalypse. Katrina Megget takes a look at the initiatives trying to support antimicrobial R&D
-
BusinessUS supreme court ends Sandoz–Amgen biosimilar dispute
Sandoz’s copy of arthritis drug Enbrel won’t be available in the US until 2029, 30 years after it was first marketed
-
OpinionThe side effects of being unique
Even the largest clinical trials won’t capture all possible bad reactions to a drug – we need pharmacovigilance
-
WebinarA recipe for success in exploiting machine learning and data science
Join us to discover how data science and big data are revolutionising decision making – and why claims that experts are no longer needed are misleading
-
WebinarStatistics versus machine learning: should we all learn artificial intelligence?
Join us to understand the limitations of deep learning & why advanced statistical modelling is still needed – both in academic curricula and in the toolbox of any scientist or engineer
-
ArticleUnlocking the future of medicines manufacturing with digital innovations
The Medicines Manufacturing Innovation Centre promises to revolutionise how we formulate, trial and produce medicines
-
BusinessAntibody–drug conjugates drive growth in oncology
Antibody–drug conjugates are coming of age and pharma is investing, reports Katrina Megget
-
OpinionHow the pandemic might change drug research
Derek Lowe muses on some positive lessons learned
-
BusinessWhy manufacturing Covid vaccines at scale is hard
Exploring the pinch points vaccine makers face as they ramp up production
-
OpinionWhy are impurity regulations different for food and drugs?
The pharmaceutical and food industries should work together more closely on genotoxic impurities
-
FeatureFlow chemistry surges forward
The long-discussed technique could help make pharma manufacturing more distributed, finds Andy Extance, and create opportunities for chemists with the right skills